SeaStar Medical (NASDAQ:ICU) Shares Up 1.3% – Here’s What Happened

by · The Cerbat Gem

SeaStar Medical Holding Corporation (NASDAQ:ICU – Get Free Report)’s stock price was up 1.3% on Monday . The company traded as high as $3.08 and last traded at $3.07. 11,203 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 47,014 shares. The stock had previously closed at $3.03.

Wall Street Analysts Forecast Growth

Several analysts have commented on ICU shares. Wall Street Zen cut shares of SeaStar Medical from a “hold” rating to a “sell” rating in a research note on Sunday, August 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of SeaStar Medical in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.00.

Read Our Latest Research Report on SeaStar Medical

SeaStar Medical Stock Performance

The company has a market cap of $13.54 million, a PE ratio of -0.79 and a beta of -1.05. The firm has a fifty day simple moving average of $3.53 and a 200 day simple moving average of $3.52.

SeaStar Medical (NASDAQ:ICU – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.06. The business had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.49 million. SeaStar Medical had a negative net margin of 795.51% and a negative return on equity of 162.75%. As a group, equities analysts predict that SeaStar Medical Holding Corporation will post -3.66 EPS for the current fiscal year.

SeaStar Medical Company Profile

(Get Free Report)

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.

Further Reading